Controversies in Hyperkalaemia Management and Practical Approaches

Published: 20 January 2022

  • Views:

    Views Icon 27173
  • Likes:

    Heart Icon 7

Overview

Controversy is good. But when it comes to hyperkalaemia management, we need solutions.

 

Chair, Prof Sydney Tang (University of Hong Kong, HK) Prof Chuan-Ming Hao (Huashan Hospital, CN) and Dr Kieran McCafferty (Queen Mary University London, UK) discuss the implementation of hyperkalaemia management strategies for patients with CKD in line with recent guidelines updates.

This symposium was endorsed by UCL and supported by an unrestricted grant from AstraZeneca

The objectives of this educational symposium are to:

  • Highlight the burden associated with hyperkalaemia and the impact this has on the use of guideline-directed medical therapy for the treatment of CKD
  • Outline the recent updates to KDIGO guidelines around the use of potassium binders to optimise RAASi
  • Explain how guideline recommendations can be translated to daily clinical practice

Target Audience

  • Cardiologists
  • Nephrologists

More from this programme

Part 1

Controversies in Hyperkalaemia Management

Overview of the symposium agenda followed by a discussion on the impact of hyperkalaemia on mortality, MACE outcomes,CKD progression and impairment of RAASi optimisation, and restriction of dietary K+. Therapeutic dilemmas and aspirations in hyperkalaemia management: interventional targets, RAASi optimisation, and low-K+diet.

Part 2

New guidelines: Advice for managing RAASi in patients with Hyperkalaemia

An overview of guidelines on the use of potassium bindersto manage hyperkalaemia and enable RAASi optimisation.

Part 3

Managing Hyperkalaemia in the real world today: A case-based study

Use of a patient case to demonstrate how new guidelines can be used in practice to enable maximal RAASi therapy.

Part 4

Panel discussion and Q&A

A discussion and Q&A with our panel.

Faculty Biographies

Chuan-Ming  Hao

Chuan-Ming Hao

Chuan-Ming Hao is the Director, a professor and the Chief Physician in the Division of Nephrology at Huashan Hospital. He is an Assistant Professor of Nephrology and Hypertension at Vanderbilt University School of Medicine, Nashville, TN, USA.

Prof Hao’s research interests focus on glomerular diseases, diabetic nephropathy, hypertension, membranous nephropathy, chronic kidney disease and uraemia. He has received research grants from FibroGen.

Prof Hao is the Vice-President of the Chinese Society of Renal Physiology, the Deputy Secretary General of the Chinese Society of Nephrology (CSN) and is the Vice-Chairman of the Kidney Physiology Professional Committee of the Chinese Association for Physiological Sciences and the Kidney Physicians Branch of the Shanghai Medical Doctor Association. In addition, he is a Standing Committee member of the Chinese Medical Doctor Association and the CSN, and a member of the American Physiological Society and the American Society…

View full profile